Debio 0228

Currently in Lead Optimization stage, the Debio 0228 program is set to identify a Development Candidate with best-in-class potential, designed to selectively destroy tumor cells that express the CAIX target. The selected compound will be developed using a theranostic approach, a combination of diagnostic and therapeutic features with the same compound, allowing the pre-identification of patients who have the receptors necessary to respond to the targeted radiotherapy